Thermo Fisher Scientific Inc. $TMO Shares Purchased by XTX Topco Ltd

XTX Topco Ltd grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 47.6% in the 2nd quarter, Holdings Channel.com reports. The fund owned 23,466 shares of the medical research company’s stock after purchasing an additional 7,565 shares during the quarter. Thermo Fisher Scientific makes up about 0.4% of XTX Topco Ltd’s holdings, making the stock its 19th largest position. XTX Topco Ltd’s holdings in Thermo Fisher Scientific were worth $9,515,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC grew its position in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Cornerstone Advisory LLC boosted its holdings in Thermo Fisher Scientific by 21.5% in the first quarter. Cornerstone Advisory LLC now owns 893 shares of the medical research company’s stock worth $444,000 after purchasing an additional 158 shares during the period. Texas Yale Capital Corp. increased its stake in Thermo Fisher Scientific by 15.1% during the first quarter. Texas Yale Capital Corp. now owns 610 shares of the medical research company’s stock valued at $304,000 after purchasing an additional 80 shares during the last quarter. Finally, LPL Financial LLC lifted its position in shares of Thermo Fisher Scientific by 6.2% in the 1st quarter. LPL Financial LLC now owns 278,299 shares of the medical research company’s stock worth $137,916,000 after buying an additional 16,362 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $585.85 on Tuesday. The firm has a 50-day moving average of $539.29 and a two-hundred day moving average of $475.16. The company has a market capitalization of $220.11 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 3.27 and a beta of 0.82. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a share repurchase program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

TMO has been the topic of several research reports. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Citigroup increased their price objective on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Argus upped their target price on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Evercore ISI increased their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Insider Activity at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 1,058 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president directly owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michel Lagarde sold 4,638 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $594.42, for a total transaction of $2,756,919.96. Following the transaction, the chief operating officer owned 23,480 shares in the company, valued at approximately $13,956,981.60. The trade was a 16.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 41,845 shares of company stock valued at $23,947,352. Corporate insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.